BLACK DIAMOND THERAPEUTICS INC (BDTX)
Health Care · oncology biotechnology · NASDAQ
A clinical-stage oncology firm using its proprietary MasterKey platform to develop precision, brain-penetrant inhibitors that target families of oncogenic mutations.
What BLACK DIAMOND THERAPEUTICS INC does
Black Diamond Therapeutics is a clinical-stage oncology company developing precision small-molecule therapies targeting families of oncogenic mutations. Its proprietary MAP drug discovery engine identifies groups of mutations with shared structural characteristics to develop inhibitors that address broad tumor types while minimizing toxicity to healthy cells. Its lead candidate, silevertinib, is a brain-penetrant, fourth-generation EGFR inhibitor being evaluated for non-small cell lung cancer (NSCLC) and glioblastoma.
Recent developments
In May 2026, the company presented positive Phase 2 data for silevertinib in frontline NSCLC patients, demonstrating an 86% CNS objective response rate. The company plans to provide an update on the pivotal development path for silevertinib in frontline NSCLC in Q4 2026. Additionally, a randomized Phase 2 trial of silevertinib in EGFRvIII+ glioblastoma (GBM) was initiated in 2026.
From BLACK DIAMOND THERAPEUTICS INC's filing of 2026-08-05.
Themes: precision oncology, targeted therapy, CNS-penetrant drugs, EGFR inhibitors, non-small cell lung cancer, glioblastoma
Fundamentals
- Price$2.07 as of 2026-10-20 close
- Market cap$119M as of 2026-07-30 (share count; price 2026-10-20)
- 1-year return-49.6% 2025-10-20 close $4.11 → 2026-10-20 close $2.07
- P/En/a negative earnings
- ROE+19.9% FY2025, SEC XBRL
- ROICn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Beta1.63 as of 2026-09-03
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How BDTX compares in its sector
- return on equitytop 25% 510 covered Health Care peers, as of 2026-09-03
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | -$12M | -$10M | -$0.17 | -$8M† | — |
| Q1 FY2026 2026-03-31 | -$11M | -$9M | -$0.16 | -$10M | — |
| Q4 FY2025 2025-12-31 | -$18M† | -$15M† | -$0.26† | -$7M† | — |
| Q3 FY2025 2025-09-30 | -$11M | -$8M | -$0.15 | -$8M† | — |
| Q2 FY2025 2025-06-30 | -$13M | -$11M | -$0.19 | -$9M† | — |
| Q1 FY2025 2025-03-31 | $55M | $57M | $0.98 | $53M | — |
| Q4 FY2024 2024-12-31 | -$18M† | -$16M† | -$0.28† | -$15M† | $0† |
| Q3 FY2024 2024-09-30 | -$18M | -$16M | -$0.28 | -$11M† | — |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$19M
- Short-term investments$91M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How BLACK DIAMOND THERAPEUTICS INC looks technically
BLACK DIAMOND THERAPEUTICS INC (BDTX) is trading 7.3% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 176 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 20, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive). It just made a new 20-day high, its first since 2026-09-09, pushing above its recent trading range. It is 58.1% below its highest point of the past year. Trading volume is running unusually high — about 3.3× its 30-day average, a sign of heightened interest.
Trend
8
| Distance from the 200-day | it is trading 7.3% below its 200-day average, the long-term trend line — a long-term downtrend | -7.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $1.98 | $1.98 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $2.23 | $2.23 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 1.6. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 176 trading days ago — a "death cross", a bearish long-term signal | 176 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 20, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend | 19.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30) | 62.8 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($1.60 to $2.13) — its "stochastic" reading is 88 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 87.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $4.94 | $4.94 |
|---|---|---|
| From the 52-week high | it is 58.1% below its 52-week high (its highest price of the past year) | -58.1% |
| Above the 52-week low | it is 29.4% above its 52-week low (its lowest price of the past year) | +29.4% |
| Below the 52-week high | it is 58.1% below its highest point of the past year | 58.1% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-09-09, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day high about 39 trading days ago | 39 sessions |
| All-time high | its highest closing price on record is $46.25 (set on 2020-06-03) | $46.25 |
| Given back of the 52-week move | over the past year its closes ranged ($1.61 to $4.87), and it has recovered only a small part of its fall from last year’s high — 14% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $3.62 to $3.73. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 14.1% |
| From the all-time high | it is 95.5% below its all-time high | -95.5% |
| Nearest price level | it is trading 2.9% above a support level at $2.01 — a price it turned at twice since 2026-03-30, most recently on 2026-09-01. Since 2024-10-21 it has 4 such levels below the current price and 12 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.9% |
| All-time low | its lowest closing price on record is $1.18 (set on 2022-10-17) | $1.18 |
| Above the all-time low | it is 75.4% above its all-time low | +75.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 73% of it) | 27th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.111 between its high and its low — about 5.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.111 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.66 and $2.01 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.66 – $1.84 – $2.01 |
| Typical daily range (% of price) | its price moves about 5.4% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.4% |
| Stretch from the 200-day average | it is trading 1.5 daily ranges below its 200-day average price (7.3% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.5 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 3.3× its 30-day average, a sign of heightened interest | 3.31× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
4
| Since a doji | 8 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 8 sessions ago |
|---|---|---|
| Since a hammer | 8 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 8 sessions ago |
| Since a bullish engulfing | 1 session ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 1 session ago |
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-20 0.6% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.6% |
|---|---|---|
| Gap filled | a 2.1% gap up opened on 2026-09-17 has been "filled" 23 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 23 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +20.35% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 4.6 percentage points (the stock gained 5.6% while the market gained 1.0%) | +4.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 10.7 percentage points (the stock gained 14.4% while the market gained 3.6%) | +10.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 40.6 percentage points (the stock lost 32.1% while the market gained 8.5%) | -40.6% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 64.2 percentage points (the stock lost 49.6% while the market gained 14.6%) | -64.2% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a fresh 20-day high, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is moderate, spanning 5.2% of the share price. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 9% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $2.28 — a volume-weighted average of daily closes over 196 sessions, not a true tick-by-tick VWAP. | -9.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $1.97 — a volume-weighted average of daily closes over 54 sessions, not a true tick-by-tick VWAP. | +5.0% |
Double bottom, bullish — broke out · entry $1.98 · 58 sessions in
Price levels it has turned at before
BDTX last closed at $2.07 on 2026-10-20. Since 2024-10-21 it has turned at 4 prices below its last close and 12 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.01 | Support | 2.9% below the last close | turned there twice · 2026-03-30 to 2026-09-01 |
| $2.13 | Resistance | 3.1% above the last close | turned there three times · 2025-02-12 to 2026-02-12 |
| $2.22 | Resistance | 7.3% above the last close | turned there four times · 2025-05-20 to 2026-07-07 |
| $1.91 | Support | 7.7% below the last close | turned there three times · 2025-01-10 to 2026-07-22 |
| $2.31 | Resistance | 11.8% above the last close | turned there four times · 2024-11-21 to 2026-08-27 |
| $1.80 | Support | 13.0% below the last close | turned there twice · 2025-05-02 to 2026-09-28 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $1.60.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 6 trading days, since 2026-10-13.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading above the 50-day moving average · Pulled back from the 12-month high · Unusually heavy trading volume · Broke out to a new 20-day high · Broke out to a new 20-day high on heavy volume | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$10.00 range $8.00 – $14.00
Analyst estimates, as of 2026-10-20. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for BDTX
- Consensus EPS estimate-$0.055 next reporting period, as of 2026-10-20
- Estimate change, 30 days$0.00 from -$0.055, on 2026-09-15, 35-day window
- Readings revised upward0% of 10 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical trial failure, delays, or failure to demonstrate safety and efficacy could materially adversely affect the company's business and stock price.","The company is highly dependent on the success of its lead product candidate, silevertinib, which is currently in development.","Substantial need for additional capital to fund clinical trials and future commercialization efforts beyond mid-2028."]
What changed in the latest 10-Q
AI-assisted comparison of BDTX's 10-Q filed 2026-08-05 against the prior one filed 2026-05-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-05) added 'including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor' to the first sentence of the Overview; older filing did not include this descriptor.
- Newer filing (2026-08-05) states 'We are advancing a Phase 2 trial in EGFRm NSCLC patients'; older filing stated 'We are advancing a Phase 2 trial in NSCLC patients' (added 'EGFRm' in newer).
- Newer filing (2026-08-05) added: 'At the American Society of Clinical Oncology (ASCO) Annual Meeting in May 2026, final clinical data from a Phase 2 trial of 83 patients with EGFRm NSCLC in the second- and third-line settings demonstrated encouraging clinical responses, robust EGFRm target coverage, and a favorable tolerability profile with no new safety signals observed.' This final-data statement replaced the older filing's 'Initial data' phrasing.
- Newer filing (2026-08-05) added a new paragraph beginning 'On May 30, 2026, data from our Phase 2 trial of silevertinib in frontline EGFRm NSCLC patients were presented at the ASCO Annual Meeting' with details dated as of an April 11, 2026 data cutoff, including: 43 frontline patients with EGFR non-classical mutations enrolled at 200 mg QD; 19 patients with brain metastases (7 with measurable CNS target lesions); median follow-up of 11.2 months; preliminary mPFS of 15.2 months (95% CI: 10.8, NE); median DOR not reached (95% CI: 7.0, NE); 23 of 43 patients (53%) remaining on therapy, longest at 23.5 months; no de novo brain metastases; previously disclosed CNS ORR (RANO-BM) of 86%, ORR (RECIST 1.1) of 60%, and DCR of 91% each remaining unchanged; VAF reductions observed in all evaluable patients across 25 unique EGFR-NCMs including PACC mutations; no new safety signals; Grade 3+ treatment-related AEs reduced to 28% after dose reductions; and support for selection of a 150 mg QD dose for pivotal development.
- Newer filing (2026-08-05) added 'of the' in 'anticipated in the first half of 2028'; older filing stated 'anticipated in the first half 2028'.
- Removed:
- Older filing (2026-05-07) contained a paragraph beginning 'In July of 2025, we completed enrollment of 43 patients in a Phase 2 trial of silevertinib in frontline NSCLC patients...' with December 2025 initial data, November 3, 2025 data cutoff, 7.2 months median follow-up, 25 confirmed partial responses and 1 confirmed complete response, 60% ORR, 86% CNS ORR, 91% DCR, 29 patients remaining on therapy (5 of 29 after progression), one patient on therapy for more than 19 months, and a statement that updated results would be presented at ASCO May 29 – June 2, 2026. This paragraph does not appear in the newer filing.
- Older filing (2026-05-07) included 'Initial data from a Phase 2 trial of 83 patients with EGFRm NSCLC in the second- and third-line settings demonstrated encouraging clinical responses...'; newer filing replaced 'Initial data' with 'final clinical data' attribution to the May 2026 ASCO Annual Meeting.
- Older filing (2026-05-07) included 'In July of 2025' and related enrollment timing language for the frontline Phase 2 trial that was removed in favor of the ASCO May 30, 2026 data paragraph in the newer filing.
- Reworded:
- Newer filing (2026-08-05) changed reference to a 'randomized Phase 2 trial of silevertinib in newly diagnosed patients with EGFRvIII+ glioblastoma (GBM), with the first patient dosed in May 2026' vs older filing's same sentence without the EGFRm qualifier in the NSCLC trial description (see additions).
- Newer filing (2026-08-05) corrected 'patents' to 'patients' in 'frontline EGFRm NSCLC patents' (older filing had typo 'patents').
- Newer filing (2026-08-05) corrected 'will be on EGFRvIII-positive patients' to 'will be EGFRvIII-positive patients' (older filing had 'will be on').
- Newer filing (2026-08-05) changed 'with potential applications in other' (older filing text truncated at 'including NSCLC, with potential applications in other' and may be cut off) - not fully assessable because both texts end mid-sentence in the section provided.
- Notes:
- Both provided MD&A excerpts end mid-sentence in the BDTX-4933 Servier paragraph, so changes after that point cannot be assessed.
- Comparison is based solely on the two provided section excerpts, not the full filings.
Risk Factors
- Removed:
- In the older filing (filed 2026-05-07), Item 5 disclosed that on February 26, 2026, Elizabeth Buck, Chief Scientific Officer, entered into a Rule 10b5-1 trading arrangement (the Buck 10b5-1 Plan) scheduled to commence on May 28, 2026 and run through May 31, 2027, with an aggregate maximum of up to 208,750 shares of common stock that may be sold.
- Reworded:
- The newer filing (filed 2026-08-05) states in Item 5 that "During the three months ended June 30, 2026, none of our officers and directors adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement," replacing the older filing's disclosure of the Buck 10b5-1 Plan and the actions taken during the three months ended March 31, 2026.
- The newer filing (filed 2026-08-05) Exhibit Index does not include Exhibit 10.1 (Amended and Restated Non-Employee Director Compensation Plan, effective January 1, 2026), which was present in the older filing (filed 2026-05-07).
- The newer filing (filed 2026-08-05) does not include the Exhibit Index note "# Indicates a management contract or any compensatory plan, contract or arrangement," which was present in the older filing (filed 2026-05-07).
- The newer filing (filed 2026-08-05) signature page is dated August 5, 2026, while the older filing (filed 2026-05-07) signature page is dated May 7, 2026.
- Notes:
- The provided texts are excerpts from Part II of each Form 10-Q; the full Risk Factors section (Item 1A) is incorporated by reference to the Annual Report on Form 10-K and not reproduced in either excerpt.
- Page numbering differs between the two filings (newer: pages 37-39; older: pages 34-37), consistent with the removal of the Exhibit 10.1 entry and associated text in the newer filing.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for BDTX — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding BDTX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 7,350,163
- Reported value $13,597,802
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about BDTX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
BDTX had 4,775,586 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
BDTX had 8.31% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.31 days to cover at the same settlement.
- Reported short interest (shares) 4,775,586
- Short interest (% of shares outstanding) 8.31%
- Prior settlement (shares) 5,147,935
- Reported change -7.23%
- Days to cover (reported) 7.31
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- AstraZeneca (AZN)
- Blueprint Medicines (BPMC)
- Mirati Therapeutics (MRTX)
- Turning Point Therapeutics (TPTX)
- Relay Therapeutics (RLAY)
- Revolution Medicines (RVMD)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare BDTX vs…
BLACK DIAMOND THERAPEUTICS INC is found in…
Frequently asked questions
What does BLACK DIAMOND THERAPEUTICS INC (BDTX) do?
Black Diamond Therapeutics is a clinical-stage oncology company developing precision small-molecule therapies targeting families of oncogenic mutations. Its proprietary MAP drug discovery engine identifies groups of mutations with shared structural characteristics to develop inhibitors that address broad tumor types while minimizing toxicity to healthy cells.
What sector is BLACK DIAMOND THERAPEUTICS INC (BDTX) in?
BLACK DIAMOND THERAPEUTICS INC (BDTX) is classified in the Health Care sector. Its industry is oncology biotechnology. It trades on NASDAQ.
Who are BLACK DIAMOND THERAPEUTICS INC's (BDTX) competitors?
Notable peers of BLACK DIAMOND THERAPEUTICS INC (BDTX) include AstraZeneca, Blueprint Medicines, Mirati Therapeutics, Turning Point Therapeutics and Relay Therapeutics. This peer set is informational only — not financial advice.
Is BLACK DIAMOND THERAPEUTICS INC (BDTX) overbought or oversold right now?
BLACK DIAMOND THERAPEUTICS INC (BDTX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 63, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on BDTX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.